KKR leads $250m pharma round

Jazz Pharmaceuticals snags one of the largest second round financings on record for a speciality pharma company without any commercialized drugs.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this